- Clinical Development
- Therapeutic Expertise
- News & Events
What makes clinical trials in orphan indications so special? Dr. Stephan de la Motte, SynteractHCR’s Chief Medical Advisor, addresses the unique characteristics of clinical trials for orphan indications in this PowerPoint primer on the topic.
Download the presentation.
SynteractHCR is a full-service CRO with more than two decades of success delivering customized Phase I-IV clinical trial solutions, contributing to numerous product approvals across multiple therapeutic areas. More...
A SynteractHCR company, The European Centre for Clinical Research Training, is recognized as an official training facility by TransCelerate BioPharma Inc. More...
SynteractHCR will make a charity contribution by collecting donations, clothes and hygiene kits to support the San Diego Rescue Mission for second year in a row More...
SynteractHCR joins the fight for breast cancer in “Making Strides Against Breast Cancer” Fundraising Walk to support the American Cancer Society More...
SynteractHCR executives outline
how we take time and cost out
of drug development with our
Intelligent Clinical Development